MindBio Therapeutics (MBIO) | WebDisclosure

Basculer en Français

8295	Companies
114850	Keywords
55292	Articles
62440	Press releases

Home
Companies
MindBio Therapeutics

BRIEF

published on 08/19/2024 at 13:25, 3 months 1 day ago

MindBio rapporte une réponse antidépressive soutenue après un traitement par microdosage

Essais Cliniques Microdosage Du LSD Traitement De Santé Mentale Thérapeutique MindBio Réponse Aux Antidépresseurs
BRIEF

published on 08/19/2024 at 13:25, 3 months 1 day ago

MindBio Reports Sustained Antidepressant Response Post Microdosing Treatment

Clinical Trials Microdosing LSD MindBio Therapeutics Mental Health Treatment Antidepressant Response
PRESS RELEASE

published on 08/19/2024 at 13:20, 3 months 1 day ago

MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
MindBio reports sustained antidepressant response in depressed patients three months post MB22001 treatment. Excellent safety and efficacy shown in Phase 2A clinical trials

MindBio Phase 2A Clinical Trials Antidepressant Response MB22001 Treatment Sustained
BRIEF

published on 08/01/2024 at 11:25, 3 months 20 days ago

MindBio Therapeutics nomme Haywood Securities pour un conseil en investissement stratégique

Investissement Stratégique Biopharmaceutique Santé Mentale Essais Cliniques Médecine Psychédélique
BRIEF

published on 08/01/2024 at 11:25, 3 months 20 days ago

MindBio Therapeutics Appoints Haywood Securities for Strategic Investment Advisory

Psychedelic Medicine Strategic Investment Clinical Trials Mental Health Biopharmaceutical
PRESS RELEASE

published on 08/01/2024 at 11:20, 3 months 20 days ago

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
MindBio Therapeutics appoints Haywood Securities Inc. as strategic advisor to support investment initiatives. Company progressing with Phase 2B clinical trials for psychedelic medicine MB22001

Psychedelic Medicine Clinical Trials Investment MindBio Therapeutics Haywood Securities Inc.
BRIEF

published on 07/08/2024 at 14:25, 4 months 12 days ago

MindBio Therapeutics CEO Updates Shareholders on Clinical Trials Progress

Clinical Trials Mental Health MB22001 MindBio Psychiatric Medicine
BRIEF

published on 07/08/2024 at 14:25, 4 months 12 days ago

Le PDG de MindBio Therapeutics informe les actionnaires des progrès des essais cliniques

MB22001 Santé Mentale Essais Cliniques Médecine Psychiatrique EspritBio
PRESS RELEASE

published on 07/08/2024 at 14:20, 4 months 12 days ago

Mindbio Therapeutics CEO Issues Letter To Shareholders
MindBio Therapeutics Corp. issues shareholder update on Phase 2B clinical trials progress, focusing on treating Major Depressive Disorder & Advanced Stage Cancer - End of Life Distress related Depression and Anxiety with MB22001 drug

MindBio Therapeutics Corp. Major Depressive Disorder Phase 2B Clinical Trials MB22001 Drug Advanced Stage Cancer
BRIEF

published on 06/20/2024 at 12:15, 5 months ago

MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials

Depression Clinical Trials MB22001 Microdosing MindBio Therapeutics

1 2 ... 7

Accesswire

Published on 11/21/2024 at 11:30, 14 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 1 hour 41 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 44 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 44 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 11 hours 9 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:30, 14 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 43 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 44 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 48 minutes ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 14 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024

Les Echos

Published on 11/21/2024 at 06:58, 4 hours 46 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 46 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 46 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 37 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 24 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE